Sector News

Categories

Borderless Insights

Image
The Skills-Forward Revolution:   Stretching the Boundaries of Professional Flexibility
Image
Sustainability: Business Leaders Must Secure the Long-Term Strategy Despite Short-Term Pressures
Image
Negotiating Terms with a New Employer

Novo Nordisk CEO sees short-term challenges to growth – paper

December 29, 2014
Life sciences
(Reuters) – Novo Nordisk, the world’s biggest insulin maker, is confident about its long-term growth plans but needs to secure approval for its new long-acting insulin Tresiba in the United States, its chief executive said in a newspaper interview on Saturday.
 
“When we look at the long-term plan … we think that we can demonstrate growth, which is near the ten percent per year,” Chief Executive Lars Rebien Sorensen told Danish daily Berlingske. “But it gets a little challenging in the short term, for it assumes, among other things, that we get Tresiba approved in the U.S.”
 
Novo Nordisk’s once-daily insulin Tresiba, the company’s big hope for the future, failed to win U.S. approval last year.
 
“If we gets Tresiba approved in the U.S. I think we will be able to grow on average 10 percent a year over the next five years,” Sorensen said.
 
The company has delivered annual growth of around 10 percent over the last decade but challenges in the United States have increased, he said.
 
“The question is how many new generations of insulin … can be developed,” he told the newspaper.
 
Sorenson pointed to competition in diabetes treatments from rivals such as Sanofi and Eli Lilly. (Reporting by Ole Mikkelsen. Editing by Jane Merriman)

comments closed

Related News

September 13, 2024

MedTrace accelerates Phase III trial and announces appointment of Nicholas Borys as Chief Medical Officer

Life sciences

Pharma and medical imaging company MedTrace announced the appointment of Nicholas Borys, M.D., as Chief Medical Officer (CMO). Dr. Borys is a skilled and experienced healthcare executive with over 25 years experience in advancing portfolios of novel therapies across diverse indications in cardiovascular, cancer, and central nervous system disease.

Read more
September 13, 2024

Eli Lilly to invest $1.8bn in manufacturing capacity in Ireland

Life sciences

Eli Lilly and Company has announced a significant expansion of its manufacturing presence in Ireland, with a $1bn investment earmarked for its Limerick site. The move is aimed at boosting the company’s production of biologic active ingredients, including those for its approved Alzheimer’s treatment.

Read more
September 13, 2024

Lonza completes expansion of microbial manufacturing facility

Life sciences

Lonza recently announced that it has completed a planned expansion of the mid-scale microbial manufacturing facility at its Visp, Switzerland site. This multi-product facility was recently granted a GMP license, allowing cGMP manufacturing and release of biologics produced using microbial fermentation.

Read more
More news